PDF(Pubmed)
Abstract：
Degenerative eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are major contributors to significant vision loss in developed nations. The primary therapeutic approach for managing complications linked to these diseases involves the intravitreal delivery of anti-vascular endothelial growth factor (VEGF) treatments. Faricimab is a novel, humanised, bispecific antibody that simultaneously binds all VEGF-A isoforms and Angiopoietin-2, which has been approved by regulatory agencies, such as the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA), for the treatment of neovascular AMD and diabetic macular oedema (DMO). Intravitreal faricimab holds the promise of reducing the treatment burden for patients with these conditions by achieving comparable or superior therapeutic outcomes with fewer clinic visits. The scope of faricimab\'s application includes addressing complex macular conditions such as DMO. This review intends to elucidate the distinctive pharmacological characteristics of faricimab and provide an overview of the key clinical trials and real-world studies that assess its effectiveness and safety in treating degenerative macular diseases.
摘要：
退行性眼病，如年龄相关性黄斑变性（AMD），糖尿病视网膜病变，在发达国家，视网膜静脉阻塞是导致严重视力丧失的主要原因。控制与这些疾病相关的并发症的主要治疗方法包括玻璃体内递送抗血管内皮生长因子(VEGF)治疗。Faricimab是一部小说,人性化,同时结合所有VEGF-A亚型和血管生成素-2的双特异性抗体，已被监管机构批准，如美国食品和药物管理局（FDA），英国药品和保健品管理局（MHRA）和欧洲药品管理局（EMA），用于治疗新生血管性AMD和糖尿病性黄斑水肿（DMO）。玻璃体内法利单抗有望通过减少就诊次数来实现可比或优越的治疗结果，从而减轻患有这些疾病的患者的治疗负担。faricimab的应用范围包括解决复杂的黄斑疾病，如DMO。这篇综述旨在阐明法利单抗的独特药理学特征，并概述评估其治疗退行性黄斑疾病的有效性和安全性的关键临床试验和现实世界研究。
